Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CDK1 | P06493 | 6/20 | 0.54 |
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17628619 | 0.90 | YTHDC1 (0.57) | YTHDC1NPC1CDK1CCNA2CDK2 | |
| SCHEMBL183315 | 0.90 | SRC (0.61) | YTHDC1SRCNPC1CDK1PRKCA | |
| SCHEMBL3352454 | 0.88 | NPC1 (0.74) | YTHDC1NPC1CDK1PRKCACCNA2 | |
| SCHEMBL29444624 | 0.88 | NPC1 (0.74) | YTHDC1NPC1CDK1PRKCACCNA2 | |
| SCHEMBL5840144 | 0.87 | CDK1 (0.65) | YTHDC1SRCNPC1CDK1CCNA2 | |
| SCHEMBL7536448 | 0.87 | YTHDC1 (0.74) | YTHDC1CDK1CCNA2CDK2HDAC1 | |
| SCHEMBL5840317 | 0.86 | CDK1 (0.68) | NPC1CDK1PRKCACCNA2CDK2 | |
| SCHEMBL6576992 | 0.84 | SRC (0.56) | YTHDC1SRCNPC1CDK1PRKCA | |
| SCHEMBL5839410 | 0.84 | CDK1 (0.69) | YTHDC1NPC1CDK1PRKCACCNA2 | |
| SCHEMBL5839910 | 0.84 | CDK1 (0.69) | NPC1CDK1PRKCACCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010059418-A1 | SUBSTITUTED TRIAZINE AND PURINE COMPOUNDS, METHODS OF INHIBITING CRUZAIN AND RHODESAIN AND METHODS OF TREATING CHAGAS DISEASE AND AFRICAN TRYPANOSOMIASIS | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) | 2010-05-27 | — | — | WO | disclosed |
| CN-1183133-C | 2-amino-6-anilino-purines and their use as medicaments | ��˹��ŵ�� | 2005-01-05 | — | — | CN | disclosed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| CN-1340054-A | 2-amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | YTHDC1 3374/4885SRC 54/4885NPC1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.